| |
|
|
|
Xtalks, Online
2025-03-04
Early glycan screening is a cornerstone for ensuring long-term biologic quality and accelerating decision-making in cell line development (CLD). Glycan profiles, as a critical quality attribute, play a pivotal role in therapeutic efficacy, stability and safety.
This webinar explores how high-throughput glycan screening integrates into the broader Solentim ecosystem for CLD automation, reducing manual effort while providing scientists with rapid, actionable clone data.
Attendees will learn from different case studies on biosimilars and glycan-engineered antibodies, discovering how automated workflows improve accuracy and efficiency while eliminating unnecessary clone progression. Whether new to CLD or optimizing existing workflows, this webinar offers practical strategies to drive biologic excellence through early glycan insights.
Register for this webinar today to discover how early glycan screening is revolutionizing cell line development by ensuring biologic quality and accelerating decision-making.
Keywords: Drug Development, Biologics, Clinical Research, CRO, Synthetic Biology, Clinical Data, Proteomics, Biologics Manufacturing, Biologics Development
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Sebastian Giehring, CEO, PAIA
Andrea Gough, Senior Director, Solentim Portfolio
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-03-04
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|